UPDATE : Tuesday, December 10, 2019
상단여백
KangStem Biotech changes strategy for atopic dermatitis drug by Jeong Sae-im 2019-10-28 15:34
Bridge Biotherapeutics passes preliminary review for Kosdaq listing by Jeong Sae-im 2019-10-25 15:05
Celltrion launches Herzuma in Brazil by Lee Han-soo 2019-10-25 13:56
KangStem Biotech fails in phase-3 study on atopic dermatitis drug by Jeong Sae-im 2019-10-25 11:17
Samsung Bioepis' biosimilar sales in EU top $180 million in Q3 by Lee Han-soo 2019-10-23 17:43
라인
Medipost wins patent for mesenchymal stem cell culture in China by Lee Han-soo 2019-10-23 16:30
Celltrion unveils clinical results of Remsima SC in treating IBD by Lee Han-soo 2019-10-22 17:00
Biogen, Samsung Bioepis to present biosimilar data at EU conference by Lee Han-soo 2019-10-22 11:31
Medytox exported ₩3.3 billion worth of unqualified BTX by Jeong Sae-im 2019-10-18 16:02
State organs squandered ₩8.2 billion; failed to spot Invossa problem by Kwak Sung-sun 2019-10-16 15:06
라인
[Exclusive] Samsung admits it failed to develop Rituxan biosimilar by Jeong Sae-im 2019-10-16 14:16
Kolon Life Science shares surge after TissueGene’s survival by Jeong Sae-im 2019-10-14 18:01
HLB merges with Elevar to own rivoceranib rights by Jeong Sae-im 2019-10-14 14:43
Samsung Bioepis to present data of Etanercept biosimilar in Europe by Lee Han-soo 2019-10-10 11:31
‘Kosdaq firms listed for exceptional tech need special monitoring’ by Jeong Sae-im 2019-10-07 15:51
라인
SK Plasma launches human immunoglobulin in Brazil by Lee Han-soo 2019-10-07 11:23
‘New law to support advanced biopharmaceuticals, ensure safety’ by Lee Hye-seon 2019-10-04 15:18
Samsung execs pass buck to biotech subsidiaries for destroying evidence by Jeong Sae-im 2019-10-04 11:42
Samsung Bioepis releases P3 results of Bevacizumab biosimilar in EU by Lee Han-soo 2019-09-27 11:37
‘Samsung BioLogics destroyed evidence to hide accounting fraud for months’ by Jeong Sae-im 2019-09-26 15:24
여백
여백
여백
Back to Top